性欲减退怎么回事

  • <tr id='uiIKrW'><strong id='uiIKrW'></strong><small id='uiIKrW'></small><button id='uiIKrW'></button><li id='uiIKrW'><noscript id='uiIKrW'><big id='uiIKrW'></big><dt id='uiIKrW'></dt></noscript></li></tr><ol id='uiIKrW'><option id='uiIKrW'><table id='uiIKrW'><blockquote id='uiIKrW'><tbody id='uiIKrW'></tbody></blockquote></table></option></ol><u id='uiIKrW'></u><kbd id='uiIKrW'><kbd id='uiIKrW'></kbd></kbd>

    <code id='uiIKrW'><strong id='uiIKrW'></strong></code>

    <fieldset id='uiIKrW'></fieldset>
          <span id='uiIKrW'></span>

              <ins id='uiIKrW'></ins>
              <acronym id='uiIKrW'><em id='uiIKrW'></em><td id='uiIKrW'><div id='uiIKrW'></div></td></acronym><address id='uiIKrW'><big id='uiIKrW'><big id='uiIKrW'></big><legend id='uiIKrW'></legend></big></address>

              <i id='uiIKrW'><div id='uiIKrW'><ins id='uiIKrW'></ins></div></i>
              <i id='uiIKrW'></i>
            1. <dl id='uiIKrW'></dl>
              1. <blockquote id='uiIKrW'><q id='uiIKrW'><noscript id='uiIKrW'></noscript><dt id='uiIKrW'></dt></q></blockquote><noframes id='uiIKrW'><i id='uiIKrW'></i>
                Jinxin Fertility Group Limited
                A
                Home > News Center

                Jinxin Fertility Announces 2019 Interim Results Actively Ex

                Jinxin Fertility Group Limited 2019-06-12 Clicks:

                  Financial Highlights

                 

                For the six months ended 30 June

                Change

                %

                2019

                (RMB Million)

                2018

                (RMB Million)

                Revenue

                791.1

                411.8

                92.1

                Gross Profit

                380.9

                190.1

                100.3

                Gross Profit Margin (%)

                48.1

                46.2

                1.9pps

                Adjusted Net Profit *

                256.6

                126.9

                102.1

                Adjusted EBITDA*

                347.1

                170.4

                103.6

                Basic Earnings per ShareRMB

                0.09

                0.14

                -35.7

                *Adjusted net profit is calculated as net profit for the Reporting Period, excluding (i) Listing expenses; (ii) ESOP expenses; (iii) amortization and depreciation of medical practice license and property, plant and equipment arising from Shenzhen Zhongshan Hospital acquisition; and (iv) imputed interest income from related parties to better reflect the Company’s current business and operations.

                *Adjusted EBITDA is calculated as EBITDA for the Reporting Period, excluding (i)Listing expenses; (ii) ESOP expenses; and (iii) amortization of medical practice license arising from Shenzhen Zhongshan Hospital acquisition; and (iv) imputed interest income from related parties to better reflect the Company’s current business and operations.

                 

                  [August 26, 2019, Hong Kong] Jinxin Fertility Group Limited (“Jinxin Fertility” or the “Company” together with its subsidiaries, the “Group”, stock code: 1951.HK), a leading assisted reproductive services (“ARS”) provider in China and the United States, announces its interim results for the half year ended June 30, 2019 (the “Period”) .

                  During the Reporting Period, revenue of the Group increased by 92.1% to approximately RMB791.1 million. The overall increase was primarily due to (i) an increase of the number of IVF patients and IVF treatment cycles performed in the Group’s Chengdu and Shenzhen operations; (ii) inclusion of the results of the United States operations into the Group starting from January 1, 2019; and (iii) completion of renovation of Shenzhen Zhongshan Hospital. Gross profit increased by 100.3% to approximately RMB380.9 million. The increase in the gross profit was mainly attributed to (i) the growth of the Group’s business; (ii) the inclusion of the results of the United States operations starting from January 1, 2019; and (iii) the increase in the scale of the Group’s operations in Chengdu and Shenzhen. Gross profit margin increased from 46.2% in the same period last year to 48.1% for the six months ended June 30, 2019. The increase in the gross profit margin was attributed to improvements in economies of scale and a change in revenue mix and higher gross profit margin generated from the United States operations. Net profit increased by 64.8% year-on-year to approximately RMB178.0 million. The Net profit margin was 22.5%, a decrease of 3.7% from 26.2% in the same period last year, which was mainly due to the increase in listing expenses.

                  During the Reporting Period, the Group increased the success rate in all three segments of our operations compared to the first half of 2018, which further reinforces our established reputation and business strategy. Operations in Shenzhen and Jinjiang IVF Center and Jinxin Fertility Center recorded an increase in the number of IVF patients and IVF treatment cycles, the number of IVF patients was 2,214 and 3,013 respectively, and the number of IVF treatment cycles was 2,909 and 3,440 respectively.While the number of IVF patients and IVF treatment cycles decreased slightly at the operations in Xinan Hospital Group primarily due to the relocation. More patients were assigned to Jinjiang IVF center to receive treatment when Chengdu Xinan Hospital went through the relocation. The consolidation of United States operations also contributed to the growth of the Group’s business in the first half of 2019.

                  Expand Operation Abilities, Enhance services experience

                  During the Reporting Period, Chengdu Xinan Hospital relocated its operations to the New Hospital Building. This relocation significantly expanded operations and provides Chengdu Xinan Hospital with the ability to serve more patients with the increased capacity, optimize and better integrate the patient treatment process, and offer more comprehensive services to its patients. Renovation of the VIP area in the New Hospital Building was completed in June 2019. We believe the new VIP area will help us offer more sophisticated services to our VIP patients. Through provision of our VIP services, the revenue generated from our network has significantly increased. Further, towards the end of June 2019, in order to further improve the patient treatment experience, renovations were completed to significantly enlarge the outpatient area of Jinjiang IVF Center from approximately 300 sq. m to 1,674 sq.m. The renovations also expanded the patient waiting area and consultation rooms. Except the improvement in the operation, Chengdu Xinan Hospital continued to provide an array of services to VIP patients to meet the increasing demand for highly personalized and private services. Furthermore, in conjunction with the OBGYN department of the Sister Group, we continued to provide patients with educational courses on pregnancy, online medical consulting and other support services, which have increased patient loyalty and the number of new patients from former patient referrals. The Group also values the experience of ethnic minority patients. In July 2019, Chengdu Xinan Hospital opened a new department to allow ethnic minority patients to better access our wide range of services.

                  Expand Research Cooperation, Actively Involve in Public Welfare

                  The Group continued to develop brand and expertise through various marketing and cooperation initiatives. As of June 30, 2019, the Group cooperated with 65 medical institutions, many of which involve two-way referrals and specialty alliance cooperation agreements. We strategically cooperated with a well-known professional salon in Japan named “Angel Baby,” in order to obtain authorization for the use of the brands Angel’s Egg (天使のたまご) and Fujiwara Angel Baby (藤原式天使ζ寶貝) to provide prenatal and postnatal acupuncture treatment and aromatherapy services at Chengdu Xinan Hospital. We expect to sign the licensing agreement in August 2019. Together with the Sichuan Provincial Trade Union, we launched the “Healthy Workplace Happy Women” public welfare speaking tour to spread awareness on infertility and assisted reproductive technology and promote our brand and competitive strengths to attract new patients. In addition, the Group entered into a cooperation agreement with the China Conservation and Research Center for Giant Pandas (the “Panda Research Center”) on April 2019 to conduct research on increasing conservation efforts of giant pandas in China. The Panda Research Center is one of the global leaders for giant panda conservation, and its primary mission is to boost the giant panda population through assisted breeding and other conservation methods.

                  In addition, HRC Fertility continued to use its extensive experience of serving Chinese patients to actively enhance its brand awareness. HRC Fertility is well-equipped with Chinese-speaking personnel (including nurses, facilitators and translators) who are familiar with the health conditions and culture of Chinese patients. We continued to organize educational seminars and information sessions to increase communication and exchanges between the medical teams of the China and United States operations. Moreover, at the end of March 2019, an official WeChat account was launched and a customer service team was established to target Chinese patients not served by the agencies in the area. Furthermore, we continued to advertise our brand through digital and traditional media outlets by publishing and promoting articles, conducting live broadcasts, granting exclusive interviews, donating our services to communities, and holding health seminars.

                  Talents Recruitment Strategy, Bolster Strong Team

                  During the Reporting Period, the Group continued to bolster its strong medical team with strategic hires of experienced medical professionals, including Dr. Lisa Becht, a well-regarded assisted reproductive physician with extensive experience in ARS. Her addition to our outstanding medical team at HRC Fertility will further increase its capacity and capability to serve more patients and provide better services. We will continue to identify and recruit experienced medical professionals in both China and the United States to our experienced medical team.

                  Increase Market Share, Improve Productivity and Capacity

                  In both China and the United States, we continue to promote market education activities that improve public awareness of our high quality services and increase our market share. Furthermore, leveraging on our existing marketing leadership in Sichuan and Guangdong, we plan to penetrate the Southwest China (such as Guizhou and Yunnan) market and use our competitive pricing in Shenzhen to expand our services to treat patients in Hong Kong.

                  Continually Invest in R&D, Enhance Overall Performance

                  Leveraging our position as one of the pioneers in the ARS industry in both China and the United States, we intend to continue to invest in research and development initiatives to maintain our leading position in the application of assisted reproductive technologies and improve clinical outcomes of our patients. The Group will continue to invest in research and development at both Chengdu and Shenzhen facilities, which have been focusing on fundamental research relating to heredity and reproductive immunology, respectively. We also focus on research to identify the physiologic appearance of embryos which are associated with higher success rates. We intend to continue to actively promote technological cooperation with tertiary institutions in China and overseas to discover new methods to improve our IVF success rates. Furthermore, we seek to actively deploy the technology that we possess to expand the services we provide.

                  Actively Expand Network, Entered Potential Markets

                  In China, we are expanding our national network by acquiring ARS providers and/or entering into cooperation arrangements with other ARS providers with an established business in populous and affluent urban centers with limited ARS providers. In the United States, we also intend to extend our services along the ARS value chain. We are able to leverage our management platform and experience in lab management to improve the success rate and attract more physicians to our network through these acquisitions. We intend to acquire embryology laboratories, surrogacy and egg donor agencies to complement HRC Fertility’s current business in the US that provides standardized services with a replicable business model and high profit margins. We would also selectively consider entering into other countries with a relatively high demand for ARS due to high infertility rates and markets that are of particular significance for providing ARS to international patients, such as Thailand and other Southeast Asia countries that are increasingly becoming medical tourism destinations for Chinese patients.

                  Mr. Wang Bin, Chairman and Non-executive Director of Jinxin Fertility emphasised that: "The Group continued to adhere to our strategy of establishing a leading global ARS platform with integrated abilities, aiming to address increasing unmet demand, in particular from Chinese patients. We have built a strong market reputation stemming from superior success rates, experienced medical staff and high quality patient care that have greatly contributed to our role as a leading ARS provider in China and the United States. With this strategy and reputation in mind, in the first half of 2019, we continued to expand our network operations, enhanced patience experience and loyalty, improved brand awareness through marketing and cooperation initiatives, recruited talent to our experienced network of physicians and increased success rates across our network of operations.”

                  About Jinxin Fertility Group Limited

                  Jinxin Fertility Group Limited listed on the Stock Exchange of Hong Kong on June 25, 2019. Jinxin Fertility is a leading assisted reproductive services (“ARS”) provider in China and the United States. The assisted reproductive medical facilities in its network in China ranked third in China’s ARS market in 2018 with 20,958 in vitro fertilization (“IVF”) treatment cycles performed and ranked first among China’s non-state-owned ARS providers in 2018 based on the same metric. The group owns and operates Chengdu Xinan Gynecological Hospital and Shenzhen Zhongshan Urological Hospital and jointly manage the IVF center of Jinjiang District Maternity and Child Health Hospital. Through its recent acquisition of HRC Management, the Group has enhanced its capabilities to provide high-value ARS to international patients, in particular, those from China. HRC Fertility is a leading full-service ARS provider in the United States with more than 30 years of experience and ranked first among all ARS providers in the United States. The group maintains its superior success rate, acquiring extensive experience and satisfying high threshold requirements for IVF licenses and the assisted reproductive medical facilities in its network in China and the United States have attained success rates higher than the national average in China and the United States, respectively.

                  - End –

                  Issued by Porda Havas International Finance Communications Group for and on behalf of Jinxin Fertility Group Limited. For further information, please contact:

                  Porda Havas International Finance Communications Group

                Kelly Fung

                +852 3150 6763

                kelly.fung@pordahavas.com

                Sharon Yu

                +852 3150 6733

                sharon.yu@pordahavas.com

                Yeri Liang

                +852 3150 6737

                yeri.liang@pordahavas.com

                  Fax: +852 3150 6728